Identify Candidates for COVID-19 Monoclonal Antibodies
Bamlanivimab/etesevimab will be the third monoclonal antibody option authorized to treat OUTpatients with COVID-19.
This combo joins bamlanivimab and casirivimab/imdevimab as another single-dose IV infusion. And more are in the works.
These “mabs” block SARS-CoV-2 from entering cells. Combo products may also limit treatment-emergent resistant viral variants.